Treatment of Discoid Lupus Erythematosus During Pregnancy or Breastfeeding

Active discoid lupus erythematosus (DLE) in a pregnant or breastfeeding patient requires a carefully selected treatment approach that balances disease control with safety for both the patient and the infant.

Clinical Scenario

This protocol addresses active CLE/DLE in patients who are currently pregnant or breastfeeding. Hydroxychloroquine (HCQ) is the recommended first-line agent in this population and may be continued or initiated during pregnancy. When HCQ does not provide adequate control, the management approach changes.

Treatment Approach — Partial Overview

For patients with active or flaring disease that has not responded adequately to hydroxychloroquine, an alternative treatment option is recommended for use during pregnancy or breastfeeding.

Full regimen — eligibility, sequencing, and complete clinical guidance — is available below.

Instant Access to Structured Evidence-Based Regimens

References

In active disease during pregnancy or breastfeeding, we recommend HCQ as first line treatment for CLE at usual dosage.
We recommend continuing the maintenance of HCQ treatment during pregnancy, but we also recommend switching from CQ to HCQ in this period.
In active disease or during flares, we suggest dapsone for HCQ-refractory CLE patients as an alternative treatment in during pregnancy or breastfeeding.

View source ↗